Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Liabilities (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Total Liabilities data on record, last reported at $52.5 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 55.11% year-over-year to $52.5 million; the TTM value through Dec 2025 reached $52.5 million, down 55.11%, while the annual FY2025 figure was $52.5 million, 55.11% down from the prior year.
  • Total Liabilities reached $52.5 million in Q4 2025 per TNGX's latest filing, up from $50.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $191.1 million in Q3 2022 and bottomed at $6.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $124.2 million, with a median of $145.6 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 2667.87% in 2021, then tumbled 59.35% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $155.4 million in 2021, then grew by 20.32% to $187.0 million in 2022, then fell by 20.07% to $149.5 million in 2023, then decreased by 21.73% to $117.0 million in 2024, then plummeted by 55.11% to $52.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $52.5 million in Q4 2025, $50.1 million in Q3 2025, and $102.9 million in Q2 2025.